Zoetis Inc. (NYSE:ZTS) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
Board of Directors has approved a multi-year share repurchase
program (the Share Repurchase Program), to which the Company may,
from time to time, purchase shares of its common stock for an
aggregate repurchase price not to exceed $1.5 billion. Share
repurchases may be executed through various means, including,
without limitation, open market or privately negotiated
transactions. The Share Repurchase Program does not have an
expiration date and does not obligate the Company to purchase any
shares. The authorization for the Share Repurchase Program may be
terminated, increased or decreased by the Companys Board of
Directors at any time. The Companys previous $500 million share
repurchase program, which was approved in November 2014, is
expected to be completed at the end of 2016. A copy of the press
release is attached hereto as Exhibit 99.1 and is incorporated by
reference into this Item 7.01.
$0.105 per share for the first quarter of 2017. The dividend will
be paid on March 1, 2017 to all holders of record of the Companys
common stock as of the close of business on January 20, 2017.
99.1, shall not be deemed filed for purposes of the Securities
Exchange Act of 1934, as amended, or incorporated by reference in
any filing under the Securities Act of 1933, as amended,
regardless of any general incorporation language in such filing,
unless expressly incorporated by specific reference in such
filing.
|
(d)
|
Exhibits:
|
About Zoetis Inc. (NYSE:ZTS)
Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. It operates through two segments: the United States and International. Within each of these segments, it offers a diversified product portfolio for both livestock and companion animal customers. In addition, its Client Supply Services (CSS) organization provides contract manufacturing services to third parties. It also offers other product categories, such as nutritionals and agribusiness. Zoetis Inc. (NYSE:ZTS) Recent Trading Information
Zoetis Inc. (NYSE:ZTS) closed its last trading session up +0.40 at 50.22 with 2,578,193 shares trading hands.
